Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MLTX vs NKTR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)

MLTX Overall Winner 6-Pillar Tally: MLTX 3 – 2 NKTR (1 Tie) Matrix Metrics: MLTX 4 – 6 NKTR

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) is the stronger overall head-to-head candidate over Nektar Therapeutics (NKTR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas NKTR carries 61.1/100 (BUY) at $36.57 (34.0x Forward P/E, -239.3% operating margin).

  • Composite vs. Pillar Nuance: While NKTR currently prints a higher short-term Unified Composite Score (61.1/100 BUY vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -239.3% operating margin) and revenue trajectory (+0.0% vs. -9.3% YoY).
  • Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile NKTR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLTX vs NKTR
MLTX NASDAQ Head-to-Head Winner
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82
NKTR NASDAQ
Nektar Therapeutics
Pharmaceutical Preparations
$36.57
-1.88% 1D
Market Cap $1.3B
TTM Revenue $55M
Forward P/E 34.0x
Beta / 30D Vol 1.10β · 48% Vol
Unified Composite Score
61.1 / 100 BUY
Tech 47.0 Fund 58.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.3%), weak momentum, RSI 35
RSI-14: 35.3 · SMA20: $37.84 · SMA50: $47.72

6-Pillar Scorecard Institutional Category Breakdown (MLTX 3 – 2 NKTR)

Columns: Metric · MLTX · NKTR
1. Valuation Multiples NKTR
Forward P/E N/M 34.0x
Trailing P/E N/M 34.0x
PEG Ratio N/M 0.31x
EV / Revenue N/M 24.0x
2. Growth & Scale NKTR
Revenue Growth (YoY) +0.0% -9.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $55M
Market Cap $1.1B $1.3B
3. Profitability & Quality MLTX
Gross Margin N/A 100.0%
Operating Margin 0.0% -239.3%
Net Profit Margin 0.0% -287.8%
Return on Equity (ROE) -81.5% -35.8%
4. Balance Sheet & Cash Flow MLTX
Cash Generation (TTM) -$244M -$234M
Cash Flow Margin N/A N/A
Net Cash / Leverage $278M Net Cash $39M Net Debt (0.09x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 111.8% (7th %ile) 76.9% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLTX (4) vs NKTR (6)
Institutional Metric MLTX NKTR Criterion Row Edge
Market Capitalization
Scale
$1.1B $1.3B Larger Scale NKTR
Trailing P/E Ratio
Valuation
N/M 34.0x Lower Multiple NKTR
Forward P/E Ratio
Valuation
N/M 34.0x Lower Multiple NKTR
Revenue Growth (YoY)
Growth
+0.0% -9.3% Higher Growth MLTX
Operating Margin (TTM)
Profitability
0.0% -239.3% Higher Margin MLTX
Net Profit Margin
Profitability
0.0% -287.8% Higher Margin MLTX
Return on Equity (ROE)
Capital Efficiency
-81.5% -35.8% Higher ROE NKTR
52-Week Range Position
Momentum
17% ($9–$23) 4% ($33–$109) Stronger Trend MLTX
Beta / 30D Volatility
Risk Regime
1.61β · 90% Vol 1.10β · 48% Vol Lower Realized Risk NKTR
Unified Institutional Score
Composite Signal
38.3 / 100 (SELL) 61.1 / 100 (BUY) Higher Composite NKTR
Trailing 12M Revenue (USD)
Operating Scale
N/A $55M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.31x PEG · 24.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$244M ($278M Net Cash) -$234M ($39M Net Debt (0.09x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLTX +21.87 pp
MLTX: +24.08% · NKTR: +2.21%
3M Horizon MLTX +22.86 pp
MLTX: -27.48% · NKTR: -50.34%
6M Horizon MLTX +18.64 pp
MLTX: -27.92% · NKTR: -46.56%
1Y Horizon MLTX +26.57 pp
MLTX: -5.65% · NKTR: -32.22%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs NKTR. Trailing 12-month operating profitability (MLTX 0.0% vs NKTR -239.3%) and valuation multiples (MLTX N/M vs NKTR 34.0x Forward P/E) are benchmarked directly in Pillar 4 below.

MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M
NKTR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$55M
Gross Margin100.0%
Op. Margin-239.3%
ROE / Fwd P/E-35.8% · 34.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NKTR BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 76.9%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NKTR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NKTR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -239.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MLTX vs NKTR Key Questions & Quantitative Answers

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) is the stronger overall head-to-head candidate over Nektar Therapeutics (NKTR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas NKTR carries 61.1/100 (BUY) at $36.57 (34.0x Forward P/E, -239.3% operating margin). Composite vs. Pillar Nuance: While NKTR currently prints a higher short-term Unified Composite Score (61.1/100 BUY vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -239.3% operating margin) and revenue trajectory (+0.0% vs. -9.3% YoY). Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile NKTR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NKTR leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NKTR at -9.3% YoY revenue growth and +0.0% YoY earnings growth on $55M TTM revenue (100.0% gross margin, -239.3% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $55M for NKTR. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NKTR.

NKTR screens cheaper on headline valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NKTR trades at 34.0x Forward P/E, 34.0x Trailing P/E, 0.31x PEG, and 24.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus NKTR (-35.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, NKTR carries 76.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.10β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.